Faculty profile

Sabrina Hoa

ResearcherMedicineUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.

Sabrina Hoa

Researcher

Medicine

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
13 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Immunosuppressive Drugs Interstitial Lung Disease Systemic Sclerosis (Scleroderma)

Latest papers

Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs.
Arthritis care & research · 2026 · first author
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.
Rheumatology (Oxford, England) · 2026
Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations.
Rheumatology advances in practice · 2026

All 26 publications

Latest funding

Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated with Systemic Sclerosis: a Feasibility Study
CIHR · 2022 · Nominated PI
$346,640

All 1 grants and awards

26 publications.

Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs.

Hoa S, Hudson M

Arthritis care & research2026First author

DOI: 10.1002/acr.80104 PMID: 42312420

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.

Ross L, Burns AT, La Gerche A, Hansen D, Coghlan JG, Stevens W, Prior D, Pham A, McKelvie P, Bellocchi C, Braun Moscovici Y, Bruni C, Carreira P, Frech T, Hoa S, Hudson M, Hsu V, Hsiu Ling Low A, Matucci-Cerinic M, Medina Fonseca B, Ng SA, Rodriguez Reyna T, Sahhar J, Talaat M, Proudman S, Vacca A, Baron M, Nikpour M, and the SCTC Cardiac Working Group

Rheumatology (Oxford, England)2026

DOI: 10.1093/rheumatology/keag109 PMID: 41758916

Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations.

Pye A, Jalaledin DS, Chang A, Saleh N, AlHajeri S, Daviault B, Shah A, Hoa S, Yu A, Levy RD, Wilson JM, Poirier CD, Choi J, Yee J, Landon Cardinal O, Kim H, Huang K

Rheumatology advances in practice2026

DOI: 10.1093/rap/rkag014 PMID: 41668977

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

Goulet D, Guertin C, Larché M, Ferdinand I, Hudson M, Choi MY, Osman M, Pope J, Thorne C, Baron M

Arthritis Care and Research20261 citationsSenior author

DOI: 10.1002/acr.80098

Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study.

Shen HC, Landon-Cardinal O, Bourré-Tessier J, Hoa S, Zarka F, Nehme J, Mansour AM, Makhzoum JP, Mereniuk A, Meunier RS, Bouchard-Marmen M, Poirier-Blanchette L, Landry M, Lévesque M, Massie R, Blanchard O, Lefebvre F, Goulet JR, Rich E, Raynauld JP, Pérez G, Koenig M, Allard-Chamard H, Drouin J, Chartrand S, Aaron M, Ivensky V, Infantino M, Giannini M, Betteridge Z, Leclair V, Hudson M, Karamchandani J, Hervier B, O'Ferrall E, Ellezam B, Targoff IN, Satoh M, Fritzler MJ, Senécal JL, Meyer A, Troyanov Y

Arthritis research & therapy2025

DOI: 10.1186/s13075-025-03662-0 PMID: 41233913

Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO).

Li JX, Hudson M, Ye C, Roberts J, Fifi-Mah A, Choi MY, Hoa S, Appleton CT, Pope J, Maltez N, Arreola LG, Obrzut A, Jamal S, Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

The Journal of rheumatology2025

DOI: 10.3899/jrheum.2024-0603 PMID: 39681372

Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology Database.

Ladouceur A, Jamal S, Saltman A, Himmel M, Hudson M, Pope J, Hoa S, Roberts J, Colmegna I, Arreola LG, Nevskaya T, Karmali A, Moon D, Schmidt E, Toban N, Cho L, Barnetche T, Ye C

ACR open rheumatology2025

DOI: 10.1002/acr2.70002 PMID: 39964344

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides

Ye C, Nikolic RPA, Choi M, Fifi-Mah AV, Graham J, O'Neil LJ, Kobza A, Lau KCK, Arreola LG, Pardo JP

Journal of Rheumatology20254 citations

DOI: 10.3899/jrheum.2025-0481

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases

Ye C, Nikolic RPA, Choi M, Fifi-Mah AV, Graham J, O'Neil LJ, Kobza A, Lau KCK, Arreola LG, Pardo JP

Journal of Rheumatology20253 citations

DOI: 10.3899/jrheum.2025-0482

Master protocol for a series of cohort-based randomized controlled trials to test tools to communicate research results to study participants and others with relevant lived experience: the SPIN-CLEAR Trials

Thombs BD, Adams C, Nassar E-L, Carrier M-E, Golberg M, Bharthi K, Wurz A, South A, Kwakkenbos L, Hoa S

Trials20252 citations

DOI: 10.1186/s13063-025-08846-2

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Immunosuppressive Drugs Dear Professor Hoa, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated with Systemic Sclerosis: a Feasibility Study" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Sabrina Hoa

Research

Latest papers

Latest funding

Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs.

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.

Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations.

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study.

Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO).

Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology Database.

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases

Master protocol for a series of cohort-based randomized controlled trials to test tools to communicate research results to study participants and others with relevant lived experience: the SPIN-CLEAR Trials

Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated with Systemic Sclerosis: a Feasibility Study

Frequent collaborators

Sabrina Hoa

Marie Hudson

Murray Baron

Janet Pope

Carrie Ye

Nancy Maltez

Margaret Larche

Jean-Paul Makhzoum

May Choi

Ines Colmegna

Carter Thorne

Jason Karamchandani

Jason Karamchandani

Faiza Khokhar

Robert Rottapel

Sasha Bernatsky

Sasha Bernatsky

Nader Khalidi

Robert Gniadecki

Shima Shahbaz

Mohammed Osman

Amanda Wurz

Vera Granikov

Elsa-Lynn Nassar

Danielle Rice

Kevin Schwartzman

Andrew Mason

Andrea Benedetti

Shokrollah Elahi

Russell Steele

Andrea Benedetti

Merrick Zwarenstein